clinical trial · NCT03737851
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
AbbVie·phase2·completed·n = 208
Multiple Sclerosis (MS)elezanumabplacebo
brief summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
started
Dec 11, 2018
primary completion
Aug 9, 2021
completion
Sep 9, 2021
last updated
Dec 22, 2023
official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol